In addition to their direct anti-tumor therapeutic potential, these antibodies can improve the selection criteria of MM patients aimed to be treated with the ImMucin anti-MUC1 SP therapeutic vaccine. The gene discussed is MUC1; the disease is Miyoshi myopathy.